Success Metrics

Active Trials
2(67%)

Phase Distribution

Ph phase_2
1
33%
Ph phase_1
2
67%

Phase Distribution

2

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Phase 1Safety & dosage
2(66.7%)
Phase 2Efficacy & side effects
1(33.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

3

all time

Status Distribution
Active(3)

Detailed Status

Active, not recruiting1
Not yet recruiting1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
2
Success Rate
N/A
Most Advanced
Phase 2

Trials by Phase

Phase 12 (66.7%)
Phase 21 (33.3%)

Trials by Status

active_not_recruiting133%
not_yet_recruiting133%
recruiting133%

Recent Activity

2 active trials
Showing 3 of 3
not_yet_recruitingphase_2

A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Lupus Nephritis

NCT07570862
recruitingphase_1

A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease

NCT06308978
active_not_recruitingphase_1

FT819 in Subjects With B-cell Malignancies

NCT04629729

Clinical Trials (3)

Showing 3 of 3 trials
NCT07570862Phase 2

A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Lupus Nephritis

Not Yet Recruiting
NCT06308978Phase 1

A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease

Recruiting
NCT04629729Phase 1

FT819 in Subjects With B-cell Malignancies

Active Not Recruiting

All 3 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
3